Perspective Therapeutics (NASDAQ:CATX) Rating Increased to Strong-Buy at Piper Sandler
Piper Sandler has upgraded Perspective Therapeutics (NASDAQ:CATX) to a "strong-buy" rating, leading to increased investor interest and a 12.3% jump in share price. The company currently holds an average rating of "Buy" from analysts with an average price target of $11.86. Institutional ownership stands at 54.66%, with several funds recently acquiring shares.
Piper Sandler initiates Perspective Therapeutics stock rating at overweight
Piper Sandler initiated coverage on Perspective Therapeutics Inc (NYSE:CATX) with an overweight rating and a $16.00 price target, citing the potential of its lead-212 radiotherapies. The firm highlighted the therapy's safety profile and the strong objective response rate shown in early trials for neuroendocrine tumors. Upcoming catalysts include data updates expected in mid-2026 and late 2026 for new combination therapies and dose-escalation studies.
Piper Sandler Initiates Coverage of Perspective Therapeutics (CATX) with Overweight Recommendation
Piper Sandler has initiated coverage of Perspective Therapeutics (CATX) with an Overweight recommendation. The analyst's one-year price target suggests a potential upside of 148.41%, with an average target of $12.50/share. The report also highlights a decrease in institutional ownership but a bullish put/call ratio, alongside significant projected revenue growth for the company.
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Perspective Therapeutics Inc. (CATX) recently raised $175 million through an underwritten offering to advance its clinical development and manufacturing facilities. The company is experiencing strong patient recruitment for its lead neuroendocrine tumor program, VMT-α-NET, which continues to show durable disease control in trials. H.C. Wainwright raised its price target for CATX to $12, citing positive clinical data and the withdrawal of a competing drug, positioning Perspective Therapeutics as a leader in radiopharmaceutical therapies.
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Perspective Therapeutics announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025, after the market closes. The company, a radiopharmaceutical development firm, is pioneering advanced treatments for cancers using its proprietary alpha-emitting isotope 212Pb. They are also developing complementary imaging diagnostics, employing a "theranostic" approach to personalize treatment and optimize patient outcomes.
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Perspective Therapeutics, Inc. announced it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025, after the market closes. The company, a radiopharmaceutical developer, is actively involved in Phase 1/2a imaging and therapy trials for various cancer treatments and is expanding its network of drug product finishing facilities. This announcement includes a safe harbor statement detailing forward-looking risks and uncertainties inherent in their clinical development and market conditions.
Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants
Perspective Therapeutics announced the pricing of an offering consisting of 39.58 million shares at $3.79 each and pre-funded warrants for up to 6.60 million shares at $3.789 per warrant, aiming to raise approximately $175 million. The company plans to use these proceeds to advance the clinical development of its radiopharmaceutical product candidates VMT-a-NET, VMT01, and PSV359, as well as for manufacturing facilities, working capital, and potential acquisitions. This financing supports Perspective's focus on innovative radiopharmaceutical treatments for various cancers, leveraging its proprietary 212 Pb alpha-emitting isotope technology.
Perspective Therapeutics shares rise after $175 million offering
Shares of radiation oncology firm Perspective Therapeutics (AMEX:CATX) rose 17.3% after announcing a $175 million follow-on offering. The company priced 46.2 million shares and warrants at $3.79 each, planning to use the proceeds for clinical development, manufacturing facilities, and potential acquisitions. This offering follows a recent surge in stock price after Sanofi deprioritized a competing radiopharmaceutical therapy.
Perspective Therapeutics jumps after $175 mln equity offering
Perspective Therapeutics (CATX) saw its stock rise following an announcement of a $175 million equity offering. The offering's financial details were released by Reuters, indicating a significant capital injection for the company. This news is expected to impact the company's financial standing and future projects.
Perspective Therapeutics (CATX) Announces $175M Public Offering
Perspective Therapeutics (CATX) has announced a public offering of 39.6 million common shares and 6.6 million pre-funded warrants, priced to raise approximately $175 million. The funds will support clinical development, manufacturing, and general corporate needs for their radiopharmaceutical cancer treatment technology. Shares saw an 11.9% premarket increase following the announcement despite the company currently reporting no revenue and negative profitability.
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering
Perspective Therapeutics announced the pricing of an underwritten public offering of 39,576,088 shares of its common stock at $3.79 per share, and pre-funded warrants for an additional 6,598,046 shares at $3.789 per warrant. The offering is expected to generate approximately $175 million in gross proceeds and is slated to close around February 3rd. The financing saw participation from several leading healthcare specialist and long-only investors.
Perspective Therapeutics taps $175M stock sale to fund cancer radiopharma work
Perspective Therapeutics (CATX) priced an underwritten offering to raise approximately $175 million by selling common shares and pre-funded warrants. The proceeds are intended to fund clinical development, manufacturing facilities, and general corporate purposes, potentially including acquisitions. This offering follows a previous $80 million raise in 2024, indicating a continued strategy of equity financing for its radiopharmaceutical pipeline, though it signals a larger negative market reaction than prior raises.
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Perspective Therapeutics, a radiopharmaceutical company, announced the pricing of a $175 million underwritten offering, consisting of common stock and pre-funded warrants. The offering is expected to close on February 3, 2026, with proceeds intended for clinical development, manufacturing facility investments, and general corporate purposes. The financing saw participation from several leading healthcare specialist investors.
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright increased its price target for Perspective Therapeutics Inc (NYSE:CATX) to $12 from $10, maintaining a Buy rating. This adjustment follows Sanofi S.A.'s decision to deprioritize its SSTR2-targeted radioimmunotherapy agent, Alphamedix, making Perspective Therapeutics' 212Pb-VMT-α-NET the sole lead-based radioimmunotherapy targeting SSTR2. The analyst firm cited recent positive clinical data presented at ASCO GU 2026 for the increase, despite other analysts like UBS and Oppenheimer lowering their price targets recently due to competitive concerns.
Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans
Perspective Therapeutics (CATX) saw its stock rise significantly after releasing updated interim data from its VMT-α-NET trial, showing sustained anti-tumor activity and a clean safety profile. The company also announced expansion plans for manufacturing, reinforcing its investment in VMT-α-NET as a key asset. While recent news has boosted market sentiment, the company remains pre-revenue, unprofitable, and dependent on external capital, with a structural risk of an inflated share price compared to its estimated value.
Perspective Therapeutics (CATX) Rating Maintained, Price Target Raised by HC Wainwright & Co. | CATX Stock News
HC Wainwright & Co. has maintained its "Buy" rating for Perspective Therapeutics (CATX) and raised its price target from $10.00 to $12.00. This follows several other analyst adjustments for CATX, with an average target price of $11.92 from 12 analysts, implying a significant upside from its current price. Perspective Therapeutics specializes in radiopharmaceutical development, utilizing Lead-212 for targeted cancer treatment.
Perspective Therapeutics (NASDAQ:CATX) Given Average Rating of "Buy" by Analysts
Six analysts have assigned an average "Buy" rating to Perspective Therapeutics (NASDAQ:CATX), with a consensus 12-month price target of $11.17. Despite this, shares recently declined by 9.4% to $3.86. Institutional investors hold over 54% of the stock, with several firms, including UBS Group AG, increasing their positions in Q4.
Perspective Therapeutics (NASDAQ:CATX) Given Outperform Rating at Wedbush
Wedbush has reiterated an "Outperform" rating for Perspective Therapeutics (NASDAQ:CATX) with an $11.00 price target, suggesting a potential 170% upside. This positive sentiment is shared by six analysts who rate the stock a "Buy," with an average target price of $11.17, although targets range from $7 to $14. The company's stock currently trades at $4.07, and institutional ownership stands at approximately 54.66%.
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright raised its price target for Perspective Therapeutics Inc (NYSE:CATX) to $12 from $10, maintaining a Buy rating, due to a competitor deprioritizing its SSTR2-targeted radioimmunotherapy agent. This development leaves Perspective Therapeutics with the sole lead-based radioimmunotherapy targeting SSTR2. The increased target also follows positive data presented at ASCO GU 2026 for its 212Pb-VMT-α-NET, showing strong patient response, despite other analysts like UBS and Oppenheimer recently lowering their price targets due to perceived competitive pressures.
Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next
Perspective Therapeutics (CATX) stock is showing volatility in premarket trading after a significant 66% surge in the previous session. Investors are closely monitoring for further price movements, filings, cash strategies, and upcoming clinical and earnings milestones, particularly given the stock's sensitivity to early trial results and funding in the radiopharmaceuticals sector. Despite sparse but positive Wall Street coverage, with BTIG Research maintaining a "buy" rating and a $14 price target, the lack of fresh news suggests the recent rally might be technically driven and could quickly reverse.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Analysts
Ten analysts have given Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) an average "Buy" rating, with six issuing a "Buy" and four a "Strong Buy." The average one-year price target is $11.50, significantly higher than its current trading price of around $2.56. The company is developing precision-targeted alpha therapies for oncology and has garnered increased positions from institutional investors like Vanguard and Bank of America.
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals
Perspective Therapeutics, Inc. has updated its corporate presentation to highlight advancements in its radiopharmaceutical platform. The presentation details its proprietary radioligand platform, the advantages of the Lead-212 isotope, and ongoing Phase 1/2a trials for VMT-⍺-NET in neuroendocrine tumors. Additionally, it mentions initial anti-tumor activity of VMT01 in melanoma trials and improved tumor retention of PSV359 in solid tumors.
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research
BTIG Research has reiterated a "Buy" rating for Perspective Therapeutics (CATX), setting a 14.00 price target that suggests a significant upside of 480.91%. Other analysts from B. Riley, UBS, and Truist Financial also maintain "Buy" ratings, with a consensus target price of $11.00. Despite this analyst optimism, the stock was trading down 15.1% at the time of the report, opening at $2.41.
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News
BTIG analyst Jeet Mukherjee has reiterated a 'Buy' rating for Perspective Therapeutics (CATX), maintaining a $14 price target. This decision aligns with a strong consensus among analysts, with other firms like Truist Securities, UBS, and B. Riley Securities also issuing 'Buy' ratings, though with varying price targets. Perspective Therapeutics is a radiopharmaceutical company focused on developing advanced treatments for cancer using its proprietary alpha-emitting isotope Lead-212 (212Pb).
Perspective Therapeutics Provides Business Updates and Strategic Priorities
Perspective Therapeutics announced important business updates and strategic priorities ahead of a major healthcare conference. The company highlighted strong patient recruitment for VMT-α-NET, with durable disease control and good tolerability. They also plan to provide clinical updates for VMT01 and PSV359 in mid to late 2026 and are expanding their manufacturing capabilities.
Perspective Therapeutics Provides Business Updates and
Perspective Therapeutics announced business updates and strategic priorities, highlighting strong patient recruitment in neuroendocrine tumors for VMT-α-NET, with clinical updates expected for VMT01 (melanoma) and PSV359 (FAP across solid tumors) in mid to late 2026. The company will present further updates at the 44th Annual J.P. Morgan Healthcare Conference. This includes an update on safety and anti-tumor activity from VMT-α-NET trials, showing durable disease control and deepening of tumor response.
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2026 ASCO Gastrointestinal Cancers Symposium. The data, with an additional 13 weeks of follow-up, show the treatment continues to be well-tolerated with durable disease control and deepening tumor responses in patients. The company also completed dose-limiting toxicity assessment for Cohort 3, allowing for further patient treatment, and plans regulatory engagement in 2026 for a registrational trial.
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics, Inc. (CATX) announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2026 ASCO Gastrointestinal Cancers Symposium. The data showed that the treatment was well-tolerated and demonstrated durable disease control and deepening tumor response in patients. The company plans further medical conference submissions and regulatory engagement in 2026 for this promising radiopharmaceutical therapy.
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data
Perspective Therapeutics (CATX) reported positive interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET for SSTR2-positive neuroendocrine tumors. The study showed favorable safety with no dose-limiting toxicities and encouraging efficacy, including a 39% objective response rate and durable disease control. This data strengthens the program's outlook for future development and registrational planning.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Brokerages
Ten brokerages have given Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) an average "Buy" rating, with a consensus one-year target price of $11.50, significantly above its current trading price of around $2.79. This positive outlook comes despite recent financial results showing a quarterly loss and negative net margin. The company specializes in precision-targeted alpha therapies for cancer and is backed by substantial institutional investment.
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4% - Should You Buy?
Perspective Therapeutics (CATX) saw its stock price rise by 0.4% to $2.75 on Wednesday, though trading volume was significantly below average. Despite an average "Buy" rating and a price target of $11.50 from analysts, several firms have recently lowered their targets, and the company's Q3 financial fundamentals remain weak with an EPS miss and negative net margin. Institutional investors hold approximately 54.66% of the company's stock.
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company specializes in radiopharmaceutical development for cancer treatment, utilizing an alpha-emitting isotope 212 Pb and complementary imaging diagnostics. Their "theranostic" approach aims to personalize treatment and optimize patient outcomes across various cancer programs, including neuroendocrine tumors, melanoma, and solid tumors.
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics, Inc. announced that its CEO, Thijs Spoor, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company specializes in radiopharmaceutical development, utilizing a "theranostic" approach with the alpha-emitting isotope 212 Pb for cancer treatment. Their programs for neuroendocrine tumors, melanoma, and solid tumors are currently in Phase 1/2a trials.
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced that its CEO, Thijs Spoor, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is a radiopharmaceutical development firm focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212 Pb technology. They are developing "theranostic" approaches, combining imaging diagnostics and targeted radiation therapy, with programs in neuroendocrine tumors, melanoma, and solid tumors.
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is a radiopharmaceutical developer focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212 Pb technology. They are also developing complementary imaging diagnostics for a theranostic approach to personalize treatment and optimize patient outcomes.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Brokerages
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received an average "Buy" rating from ten brokerages, with an average 12-month price target of $11.50. The company is developing precision-targeted alpha therapies, with lead candidates VMT-a-NET and VMT01 in Phase 1/2a clinical trials. Despite strong liquidity, the company is currently loss-making, with analysts forecasting an EPS of -0.88 for the current fiscal year.
Perspective Therapeutics Announces Acceptance of VMT-α-NET
Perspective Therapeutics announced that updated data from its [212 Pb]VMT-α-NET program have been accepted for presentation at the ASCO Gastrointestinal Cancers Symposium 2026. This data will focus on the safety and preliminary efficacy of [212 Pb]VMT-α-NET in advanced, SSTR2-expressing neuroendocrine tumors. The Company's ongoing study shows the treatment continues to demonstrate a favorable safety profile and anti-tumor activity.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics announced that updated data from its [²¹²Pb]VMT-α-NET program have been accepted for presentation at the ASCO-GI Congress 2026. The data relate to the safety and preliminary efficacy of a radiopharmaceutical therapy for neuroendocrine tumors. The presentation will occur on January 9, 2026, and further details will be released by ASCO-GI on January 5, 2026.
Perspective Therapeutics (NYSE: CATX) to Present VMT-α-NET Data at 2026 ASCO-GI
Perspective Therapeutics announced that updated data for its R&D program, [212Pb]VMT-α-NET, has been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026. The presentation will cover safety and preliminary efficacy results in advanced SSTR2-expressing neuroendocrine tumors. This news led to an 8.14% increase in CATX stock, adding approximately $13M to the company's valuation.
Perspective Therapeutics to Participate in Upcoming December Conferences
Perspective Therapeutics, Inc. announced that its senior leadership will attend the Piper Sandler & Co. 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. During these events, company representatives will participate in fireside chats and engage in one-on-one meetings with investors. The company focuses on developing advanced radiopharmaceutical treatments for various cancers using its proprietary alpha-emitting isotope 212 Pb technology.
UBS lowers Perspective Therapeutics stock price target on competition concerns
UBS has reduced its price target for Perspective Therapeutics (NYSE:CATX) to $7.00 from $18.00 due to intensifying competition affecting the commercial adoption of its lead program, [212Pb] VMT-α-NET. Despite the lower target, which still offers significant upside, the analyst consensus remains largely bullish. The company is expected to release new data in early 2026, which may influence future efficacy assessments.
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation
UBS has reiterated its "Buy" recommendation for Perspective Therapeutics (NYSEAM:CATX) following a report by Fintel. The average one-year price target of $13.41/share suggests a potential upside of 532.35% from its last closing price. Institutional ownership in CATX remains strong, with a slight decrease in the number of funds reporting positions but an increase in total shares owned.
UBS lowers Perspective Therapeutics stock price target on competition concerns
UBS has lowered its price target for Perspective Therapeutics Inc (NYSE:CATX) to $7.00 from $18.00 due to concerns about increased competition impacting its lead program, [212Pb] VMT-α-NET, despite maintaining a Buy rating. This adjustment reflects a reduced peak penetration estimate and sales forecast for the drug, even as the company continues to release promising clinical trial data. The article also notes other analyst actions, with Oppenheimer lowering its target, while BTIG and H.C. Wainwright initiated or reiterated Buy ratings.
Perspective Therapeutics to Participate in Upcoming December Conferences
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced that its senior leadership team will participate in two December healthcare conferences: the Piper Sandler & Co. 37th Annual Healthcare Conference and the Evercore 8th Annual Healthcare Conference. The company will be available for one-on-one meetings with investors at both events to discuss its pioneering radiopharmaceutical treatments for various cancers. Perspective Therapeutics is focused on developing therapies utilizing the alpha-emitting isotope 212 Pb and complementary imaging diagnostics.
Perspective (CATX) to meet investors at Piper Sandler and Evercore healthcare events
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that its senior leadership will participate in two investor conferences in early December 2025. This includes fireside chats and one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference in New York and the Evercore 8th Annual Healthcare Conference in Miami. The company, focused on radiopharmaceutical development for cancers, will discuss its advanced treatments and theranostic approach.
Perspective Therapeutics to Participate in Upcoming December Conferences
Perspective Therapeutics, Inc. announced that its senior leadership team will participate in two upcoming December conferences. The company's representatives will engage in fireside chats and one-on-one meetings with investors at the Piper Sandler & Co. 37th Annual Healthcare Conference and the Evercore 8th Annual Healthcare Conference. Perspective Therapeutics is a radiopharmaceutical development company focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212 Pb technology.
B. Riley Securities Maintains Perspective Therapeutics (CATX) Buy Recommendation
B. Riley Securities has reiterated its "Buy" recommendation for Perspective Therapeutics (CATX), with an average one-year price target of $13.41, suggesting a significant upside of 506.60%. The article details the company's projected annual revenue increase of 960.47% and provides insights into institutional ownership and fund sentiment. Key institutional holders and their recent adjustments in CATX shares are also highlighted.
Perspective Therapeutics, Inc Updates Corporate Presentation
Perspective Therapeutics, Inc. has updated its corporate presentation to highlight advancements in its radiopharmaceutical platform, including forward-looking statements on clinical development plans. The presentation emphasizes innovative platform technology for targeted cancer therapies and multiple clinical-stage programs with significant milestones expected through 2026. The company has also strengthened its radioisotope supply chain to support manufacturing and distribution, aiming for potential market expansion in various cancer indications.
Williamson buys Perspective Therapeutics (CATX) shares worth $19,945
Director Robert F. Williamson III purchased 9,498 shares of Perspective Therapeutics, Inc. (NASDAQ:CATX) common stock for $19,945 on November 12, 2025. Following this transaction, Williamson directly holds 108,982 shares and indirectly 9,864 shares. This insider trade occurred amidst varying analyst opinions and recent clinical trial data for the company's cancer treatment.
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Perspective Therapeutics, Inc. will report its third-quarter 2025 financial results and provide a business update on Monday, November 10, 2025, after market close. The company, which specializes in radiopharmaceutical development for cancer treatments, utilizes alpha-emitting isotope 212 Pb and complementary imaging diagnostics in its theranostic approach. Their programs, including those for neuroendocrine tumors, melanoma, and solid tumors, are currently in Phase 1/2a imaging and therapy trials in the U.S.
